NCT05540925View on ClinicalTrials.gov

Vascular Invasion Signatures in cfDNA Support Re-staging of Liver Cancer

CompletedOBSERVATIONAL

Enrollment

286

Participants

Timeline

Start Date

January 1, 2022

Primary Completion Date

June 1, 2022

Study Completion Date

September 1, 2022

Conditions

Carcinoma, HepatocellularHepatocellular CancerLiver Cancer

Interventions

PROCEDURE

Liver resection

"All patients underwent curative-intent resection for early-stage HCC (a solitary tumor nodule≤5 cm, or multiple nodules≤3, each≤3 cm).~We did not take any other intervention. We retrospectively analyzed the prognostic performance of patients with wide (≥1cm) or narrow (\<1cm) resection margin in different groups."

Trial Locations (1)

021

Eastern Hepatobiliary Surgery Hospital, Naval Medical University,, Shanghai

All Listed Sponsors

lead

Eastern Hepatobiliary Surgery Hospital

OTHER

NCT05540925 - Vascular Invasion Signatures in cfDNA Support Re-staging of Liver Cancer | Biotech Hunter | Biotech Hunter